

Thursday | 23 October | 12:00 – 13:00  
International Barcelona Convention Center | Hall 114



**LUNCH  
PACKAGE  
FOR FREE**

## **Breakthroughs in AIS Therapy:** Recent trial results in evidence-based cerebroprotection

Chair: **Jennifer Manzano (Philippines)**

**Sławomir Michalak (Poland)**

Circulating Tight Junction Proteins in Acute Ischemic Stroke Patients after  
Reperfusion Therapy combined with Cerebrolysin

**Daniel Šaňák (Czech Republic)**

CREGS – Results of a large High-Quality Comparative  
Effectiveness Research Study

### **"Scales Booklet"**

*Essential Clinical Rating Scales - From acute Stroke to Neurorehabilitation.*

Visit our EVER Satellite Symposium and you will receive a quick guide to important rating  
scales regarding stroke assessment, stroke treatment and stroke rehabilitation outcome.



## SMALL MOMENT. BIG DIFFERENCE.

Last month, Paul was suffering from cognitive and motor impairment.  
**Today, he's making his next big move.**

- Improvement of motor functions
- Early recovery after stroke
- Regain full independence
- Increase quality of life

Muresanu, et al., 2016

**ABBREVIATED PRESCRIBING INFORMATION:** Name of the medicinal product: Cerebrolysin® - Solution for injection. Qualitative and quantitative composition: One ml contains 215.2 mg of porcine brain-derived peptide preparation (Cerebrolysin® concentrate) in aqueous solution. List of excipients: Sodium hydroxide and water for injection. Therapeutic indications: Organic, metabolic and neurodegenerative disorders of the brain, especially senile dementia of Alzheimer's type - Post-apoplectic complications - Craniocerebral trauma; post-operative trauma, cerebral contusion or concussion. Contraindications: Hypersensitivity to one of the components of the drug, epilepsy, severe renal impairment. Marketing Authorisation Holder: EVER Neuro Pharma GmbH, A-4866 Unterach. Only available on prescription and in pharmacies. More information about pharmaceutical form, posology and method of administration, special warnings and precautions for use, interaction with other medicinal products and other forms of interaction, fertility, pregnancy and lactation, effects on ability to drive and use machines, undesirable effects, overdose, pharmacodynamics properties, pharmacokinetic properties, preclinical safety data, incompatibilities, shelf life, special precautions for storage, nature and contents of the container and special precautions for disposal is available in the summary of product characteristics.



# Cerebrolysin®

**Reconnecting Neurons.  
Empowering for Life.**